The future role of personalized medicine in the treatment of glioblastoma multiforme [0.03%]
个性化医疗在胶质母细胞瘤治疗中的未来作用
Jing Li,Chunhui Di,Austin K Mattox et al.
Jing Li et al.
Glioblastoma multiforme (GBM) remains one of the most malignant primary central nervous system tumors. Personalized therapeutic approaches have not become standard of care for GBM, but science is fast approaching this goal. GBM's heterogene...
Eugene Lin,Rajiv Padmanabhan,Majaz Moonis
Eugene Lin
Introduction: Antiplatelet therapy remains one of the cornerstones in the management of non-cardioembolic ischemic stroke. However, a significant percentage of patients have concomitant gastroesophageal reflux or peptic u...
Kena J Lanham,Julie H Oestreich,Steven P Dunn et al.
Kena J Lanham et al.
Antithrombotic therapy, including anticoagulants as well as antiplatelet drugs, is an important component in the treatment of cardiovascular disease. Variability in response to such medications, of which pharmacogenetic response is a major ...
Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab [0.03%]
胶质母细胞瘤多形体的治疗更新和进展-重点介绍贝伐单抗
Naveed Wagle,Leia Nghiemphu,Albert Lai et al.
Naveed Wagle et al.
Glioblastoma is the most common primary brain tumor with a relatively poor prognosis. This article reviews the current standard therapy and discusses new developments in treatment of this disease. Surgical resection followed by radiation an...
DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics [0.03%]
多动症中的DRD4和DAT1：从功能神经生物学到药理遗传学
Darko Turic,James Swanson,Edmund Sonuga-Barke
Darko Turic
Attention deficit/hyperactivity disorder (ADHD) is a common and potentially very impairing neuropsychiatric disorder of childhood. Statistical genetic studies of twins have shown ADHD to be highly heritable, with the combination of genes an...
Thomas S Lin
Thomas S Lin
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependen...
Determinants to optimize response to clopidogrel in acute coronary syndrome [0.03%]
急性冠脉综合征患者氯吡格雷反应性的决定因素
Betti Giusti,Anna Maria Gori,Rossella Marcucci et al.
Betti Giusti et al.
The inhibition of platelet function by antiplatelet therapy determines the improvement of the survival of patients with clinically evident cardiovascular disease. Clopidogrel in combination with aspirin is the recommended standard of care f...
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies [0.03%]
类风湿关节炎的药物基因学：来自易感基因和现有治疗药物的潜在靶点
Darren D O&#x;Rielly,Proton Rahman
Darren D O&#x;Rielly
Rheumatoid arthritis (RA) is a chronic heterogeneous autoimmune disorder of unknown etiology resulting in inflammation in the synovium, cartilage, and bone. Genetic factors play an important role in susceptibility to RA as the heritability ...
Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin [0.03%]
聚乙二醇干扰素与利巴韦林个体化治疗慢性丙型肝炎
Roberto J Carvalho-Filho,Olav Dalgard
Roberto J Carvalho-Filho
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with perhaps 180 million people infected worldwide. A significant proportion of these will eventually develop clinical complications, such as cirrhosis, liver ...
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent [0.03%]
非洲血统的HIV-1感染患者的药物基因组学对治疗的意义及影响
Hector Clarke,Shaker A Mousa
Hector Clarke
One of the great advances in the treatment of HIV-1 infection was the development of the highly active antiretroviral therapy (HAART). Although this treatment strategy is highly effective in many individuals, interpatient variability of dru...